Green light for primary progressive MS drug

NICE reverses its decision on ocrelizumab Related items fromOnMedica Clinicians need better options if we are to stop over-medication Call for NHS England to ‘think again’ on limiting treatment Wales cancer spend at record high Resources wasted on low-risk blood pressure patients NHS saves £324m by switching to cheaper medicines
Source: OnMedica Latest News - Category: UK Health Source Type: news